Captor Therapeutics SA received from NCBiR two grants of nearly 56 M PLN to advance the development of targeted therapies against colorectal cancer and broad range of autoimmune disorders.
„Development of first-in-class drug candidate, small molecule degrader, for the therapy against colorectal cancer” (POIR.01.02.00-00-0073/18) and „Application of targeted protein degradation technology in the therapy against psoriasis and rheumatoid arthritis” (POIR.01.02.00-00-0079/18) projects are co-financed by European Regional Development Fund within Competition 3/1.2/2018 InnoNeuroPharm Sectoral Program.
Share:
